Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bioterror Investor Fund Would Get $20 Mil. Ante Under Senate Appropriations Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

Funding for the Cures Acceleration Network would also be increased, to $40 million in fiscal 2013, under the legislation marked up by the Appropriations subcommittee; the full committee will work on the bill June 14.

You may also be interested in...



NIH Translational Science Center Would Get 10% Funding Boost In Senate Bill

Appropriations Committee recommends BARDA receive a 12% increase over its fiscal 2012 appropriations in the report accompanying the Departments of Labor, Health and Human Services and Education, and Related Agencies Appropriations bill sent to the floor on a party-line vote of 16-14, June 14.

NIH Royalties For Pfizer, AstraZeneca, Lilly Drugs Remain Open Question In Repurposing Initiative

With collaborative research agreement templates that include many of the details for a licensing agreement, royalties will be the major issue to be resolved if researchers develop new IP for one of the firm’s abandoned compounds.

NIH’s Translational Science Center Could See Budget Trimmed

Republicans on appropriations subcommittee again seem concerned about whether NCATS will trample industry toes, which could lead to a more tightened focus for the new NIH center’s funding in the upcoming bill.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel